Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effectiveness and safety of the regimen
including high dose rifampicin for individualized duration (3 months after Culture
Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Phase:
Phase 3
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Chonnam National University Hospital International Tuberculosis Research Center Korean Center for Disease Control and Prevention Korean Institute of Tuberculosis National Medical Center, Seoul Pusan National University Hospital Pusan National University Yangsan Hospital Seoul National University Bundang Hospital Severance Hospital SMG-SNU Boramae Medical Center